Hepatitis C virus infection in patients and family members attending two primary care clinics in Puebla, Mexico
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 6
Abstract
Background. Approximately 180 million persons (~2.8%) globally are estimated to be infected by hepatitis C virus (HCV). HCV prevalence in Mexico has been estimated to be between 1.2 and 1.4%. The aim of present work was to determine the prevalence of HCV infection in patients and family members attending two primary care clinics in Puebla, Mexico. Material and methods. Patients and their accompanying family members in two clinics were invited to participate in this study between May and September 2010. Results. A total of 10,214 persons were included in the study; 120 (1.17%) persons were anti-HCV reactive. Of the reactive subjects, detection of viral RNA was determined in 114 subjects and 36 were positive (31%). The more frequent risk factors were having a family history of cirrhosis (33.1%) and having a blood transfusion prior to 1995 (29%). After a multiple logistic regression analysis only transfusion prior to 1995 resulted significant to HCV transmission (p = 0.004). The overall detected HCV genotypes were as follows: 1a (29%), 1b (48.5%), 2/2b (12.8%), and 3a (6.5%). Conclusion. The HCV prevalence in this population is in agreement with previous studies in other regions of Mexico.
Authors and Affiliations
Aurelio López-Colombo, Daniel Meléndez-Mena, Virginia Sedeño-Monge, José R. Camacho-Hernández, Eduardo Vázquez-Cruz, Eduardo R. Morales-Hernández, Francisca Sosa-Jurado, Luis Márquez-Domínguez, Gerardo Santos-López
Keywords
Related Articles
- EP ID EP78450
- DOI -
- Views 135
- Downloads 0
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinom...
The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers
The early diagnosis of primary sclerosing cholangitis, hepatocellular carcinoma, and cholangiocarcinoma is often challenging. In a recent study in 134 patients (Arbelaiz, Hepatology 2017; 66:1125-1143), it was reported t...
Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B
Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) antibody seroconversion is the best, final objective for all available chronic hepatitis B (CHB) treatments. Unfortunately, this goal is rarely obt...
Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
[b]Background[/b]. Probiotics have profound effect on nonalcoholic steatohepatitis (NASH) in animal models. We aimed to test the hypothesis that probiotics treatment was superior to usual care in reducing liver fat in NA...
High frequencies of CD158b+ NK cells are associated with persistent hepatitis C virus infections
Background. During the early phases of a hepatitis C virus (HCV) infection, NK cell activation appears to be critical to the induction of adaptive immune responses that have the potential of clearing the infection. This...